APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza (Flu) Antiviral Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026

2 January 2026218 pages

Choose your research edition.

Industry ResearchInfluenza (Flu) Antiviral Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Influenza (Flu) Antiviral Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Influenza (Flu) Antiviral Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Influenza (Flu) Antiviral Drugs market include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza (Flu) Antiviral Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza (Flu) Antiviral Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza (Flu) Antiviral Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza (Flu) Antiviral Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza (Flu) Antiviral Drugs Segment by Company

Allergan

Aurobindo Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers-Squibb

Cipla

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline (GSK)

Merck & Co. (MSD)

Novo Nordisk

Teva Pharmaceutical Industries

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Novartis

Johnson & Johnson

Sanofi

Teva

Takeda

Influenza (Flu) Antiviral Drugs Segment by Type

Neuraminidase Inhibitors

Reverse Transcriptase Inhibitors

Broad-spectrum Antiviral Drugs

Protein Inhibitors

Penetration and Dehulling Inhibitors

DNA Polymerase Inhibitors

Influenza (Flu) Antiviral Drugs Segment by Application

Clinic

Hospital

Household

Others

Influenza (Flu) Antiviral Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Influenza (Flu) Antiviral Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Influenza (Flu) Antiviral Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenza (Flu) Antiviral Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Influenza (Flu) Antiviral Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza (Flu) Antiviral Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza (Flu) Antiviral Drugs industry.

Chapter 3: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Influenza (Flu) Antiviral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Influenza (Flu) Antiviral Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenza (Flu) Antiviral Drugs Industry Trends Table 2. Influenza (Flu) Antiviral Drugs Industry Drivers Table 3. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges Table 4. Influenza (Flu) Antiviral Drugs Industry Restraints Table 5. Global Influenza (Flu) Antiviral Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenza (Flu) Antiviral Drugs Revenue Share by Company (2021-2026) Table 7. Global Influenza (Flu) Antiviral Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Influenza (Flu) Antiviral Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Influenza (Flu) Antiviral Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Influenza (Flu) Antiviral Drugs Company, Product Type & Application Table 13. Global Influenza (Flu) Antiviral Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza (Flu) Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Neuraminidase Inhibitors Table 18. Significant Companies of Reverse Transcriptase Inhibitors Table 19. Significant Companies of Broad-spectrum Antiviral Drugs Table 20. Significant Companies of Protein Inhibitors Table 21. Significant Companies of Penetration and Dehulling Inhibitors Table 22. Significant Companies of DNA Polymerase Inhibitors Table 23. Global Influenza (Flu) Antiviral Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Influenza (Flu) Antiviral Drugs Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Influenza (Flu) Antiviral Drugs Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Influenza (Flu) Antiviral Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Influenza (Flu) Antiviral Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Influenza (Flu) Antiviral Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Type (2021-2026) Table 32. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Household Table 36. Significant Companies of Others Table 37. Global Influenza (Flu) Antiviral Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Influenza (Flu) Antiviral Drugs Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Influenza (Flu) Antiviral Drugs Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Application (2021-2026) Table 41. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Application (2027-2032) Table 42. Global Influenza (Flu) Antiviral Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Influenza (Flu) Antiviral Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Influenza (Flu) Antiviral Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Application (2021-2026) Table 46. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Application (2027-2032) Table 47. Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units) Table 49. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2026) Table 50. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (K Units) Table 51. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2027-2032) Table 52. Global Influenza (Flu) Antiviral Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Influenza (Flu) Antiviral Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Region (2021-2026) Table 55. Global Influenza (Flu) Antiviral Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Region (2027-2032) Table 57. Global Influenza (Flu) Antiviral Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Influenza (Flu) Antiviral Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Influenza (Flu) Antiviral Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 62. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 63. Global Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 64. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2027-2032) Table 65. Global Influenza (Flu) Antiviral Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Influenza (Flu) Antiviral Drugs Sales Value Market Share by Country (2021-2026) Table 67. Global Influenza (Flu) Antiviral Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Influenza (Flu) Antiviral Drugs Sales Value Market Share by Country (2027-2032) Table 69. Allergan Company Information Table 70. Allergan Business Overview Table 71. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio Table 73. Allergan Recent Development Table 74. Aurobindo Pharma Company Information Table 75. Aurobindo Pharma Business Overview Table 76. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio Table 78. Aurobindo Pharma Recent Development Table 79. Boehringer Ingelheim Company Information Table 80. Boehringer Ingelheim Business Overview Table 81. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio Table 83. Boehringer Ingelheim Recent Development Table 84. Bristol-Myers Squibb Company Information Table 85. Bristol-Myers Squibb Business Overview Table 86. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 88. Bristol-Myers Squibb Recent Development Table 89. Bristol-Myers-Squibb Company Information Table 90. Bristol-Myers-Squibb Business Overview Table 91. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 93. Bristol-Myers-Squibb Recent Development Table 94. Cipla Company Information Table 95. Cipla Business Overview Table 96. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio Table 98. Cipla Recent Development Table 99. F. Hoffmann-La Roche Company Information Table 100. F. Hoffmann-La Roche Business Overview Table 101. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 103. F. Hoffmann-La Roche Recent Development Table 104. Gilead Sciences Company Information Table 105. Gilead Sciences Business Overview Table 106. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio Table 108. Gilead Sciences Recent Development Table 109. GlaxoSmithKline (GSK) Company Information Table 110. GlaxoSmithKline (GSK) Business Overview Table 111. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio Table 113. GlaxoSmithKline (GSK) Recent Development Table 114. Merck & Co. (MSD) Company Information Table 115. Merck & Co. (MSD) Business Overview Table 116. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio Table 118. Merck & Co. (MSD) Recent Development Table 119. Novo Nordisk Company Information Table 120. Novo Nordisk Business Overview Table 121. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio Table 123. Novo Nordisk Recent Development Table 124. Teva Pharmaceutical Industries Company Information Table 125. Teva Pharmaceutical Industries Business Overview Table 126. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio Table 128. Teva Pharmaceutical Industries Recent Development Table 129. AstraZeneca Company Information Table 130. AstraZeneca Business Overview Table 131. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio Table 133. AstraZeneca Recent Development Table 134. AbbVie Company Information Table 135. AbbVie Business Overview Table 136. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio Table 138. AbbVie Recent Development Table 139. Amgen Company Information Table 140. Amgen Business Overview Table 141. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio Table 143. Amgen Recent Development Table 144. Bayer Company Information Table 145. Bayer Business Overview Table 146. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio Table 148. Bayer Recent Development Table 149. Pfizer Company Information Table 150. Pfizer Business Overview Table 151. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio Table 153. Pfizer Recent Development Table 154. Eli Lilly Company Information Table 155. Eli Lilly Business Overview Table 156. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio Table 158. Eli Lilly Recent Development Table 159. Roche Company Information Table 160. Roche Business Overview Table 161. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 163. Roche Recent Development Table 164. Mylan Company Information Table 165. Mylan Business Overview Table 166. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio Table 168. Mylan Recent Development Table 169. Novartis Company Information Table 170. Novartis Business Overview Table 171. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio Table 173. Novartis Recent Development Table 174. Johnson & Johnson Company Information Table 175. Johnson & Johnson Business Overview Table 176. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio Table 178. Johnson & Johnson Recent Development Table 179. Sanofi Company Information Table 180. Sanofi Business Overview Table 181. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio Table 183. Sanofi Recent Development Table 184. Teva Company Information Table 185. Teva Business Overview Table 186. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. Teva Influenza (Flu) Antiviral Drugs Product Portfolio Table 188. Teva Recent Development Table 189. Takeda Company Information Table 190. Takeda Business Overview Table 191. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio Table 193. Takeda Recent Development Table 194. Key Raw Materials Table 195. Raw Materials Key Suppliers Table 196. Influenza (Flu) Antiviral Drugs Distributors List Table 197. Influenza (Flu) Antiviral Drugs Customers List Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources Table 201. Primary Sources List of Figures Figure 1. Influenza (Flu) Antiviral Drugs Product Image Figure 2. Global Influenza (Flu) Antiviral Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units) Figure 5. Global Influenza (Flu) Antiviral Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Influenza (Flu) Antiviral Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Neuraminidase Inhibitors Image Figure 10. Reverse Transcriptase Inhibitors Image Figure 11. Broad-spectrum Antiviral Drugs Image Figure 12. Protein Inhibitors Image Figure 13. Penetration and Dehulling Inhibitors Image Figure 14. DNA Polymerase Inhibitors Image Figure 15. Global Influenza (Flu) Antiviral Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Influenza (Flu) Antiviral Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Influenza (Flu) Antiviral Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Influenza (Flu) Antiviral Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Household Image Figure 24. Others Image Figure 25. Global Influenza (Flu) Antiviral Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Influenza (Flu) Antiviral Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Application (2021-2032) Figure 28. Global Influenza (Flu) Antiviral Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Influenza (Flu) Antiviral Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Application (2021-2032) Figure 31. Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Influenza (Flu) Antiviral Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Influenza (Flu) Antiviral Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. North America Influenza (Flu) Antiviral Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Influenza (Flu) Antiviral Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. South America Influenza (Flu) Antiviral Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Influenza (Flu) Antiviral Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Influenza (Flu) Antiviral Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Influenza (Flu) Antiviral Drugs Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Influenza (Flu) Antiviral Drugs Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Broad-spectrum Antiviral Drugs
  • Protein Inhibitors
  • Penetration and Dehulling Inhibitors
  • DNA Polymerase Inhibitors
Applications
  • Clinic
  • Hospital
  • Household
  • Others
Companies covered
  • Allergan
  • Aurobindo Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Merck & Co. (MSD)
  • Novo Nordisk
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Influenza (Flu) Antiviral Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Influenza (Flu) Antiviral Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Influenza (Flu) Antiviral Drugs Market Dynamics
  1. 2.1 Influenza (Flu) Antiviral Drugs Industry Trends
  2. 2.2 Influenza (Flu) Antiviral Drugs Industry Drivers
  3. 2.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza (Flu) Antiviral Drugs Industry Restraints
3 Influenza (Flu) Antiviral Drugs Market by Company
  1. 3.1 Global Influenza (Flu) Antiviral Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Influenza (Flu) Antiviral Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Influenza (Flu) Antiviral Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Influenza (Flu) Antiviral Drugs Company Ranking (2024-2026)
  6. 3.6 Global Influenza (Flu) Antiviral Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Influenza (Flu) Antiviral Drugs Company Product Type and Application
  8. 3.8 Global Influenza (Flu) Antiviral Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Influenza (Flu) Antiviral Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Influenza (Flu) Antiviral Drugs Market by Type
  1. 4.1 Influenza (Flu) Antiviral Drugs Type Introduction
  2. 4.1.1 Neuraminidase Inhibitors
  3. 4.1.2 Reverse Transcriptase Inhibitors
  4. 4.1.3 Broad-spectrum Antiviral Drugs
  5. 4.1.4 Protein Inhibitors
  6. 4.1.5 Penetration and Dehulling Inhibitors
  7. 4.1.6 DNA Polymerase Inhibitors
  8. 4.2 Global Influenza (Flu) Antiviral Drugs Sales Volume by Type
  9. 4.2.1 Global Influenza (Flu) Antiviral Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Influenza (Flu) Antiviral Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Influenza (Flu) Antiviral Drugs Sales Value by Type
  13. 4.3.1 Global Influenza (Flu) Antiviral Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Influenza (Flu) Antiviral Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Influenza (Flu) Antiviral Drugs Sales Value Share by Type (2021-2032)
5 Influenza (Flu) Antiviral Drugs Market by Application
  1. 5.1 Influenza (Flu) Antiviral Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Household
  5. 5.1.4 Others
  6. 5.2 Global Influenza (Flu) Antiviral Drugs Sales Volume by Application
  7. 5.2.1 Global Influenza (Flu) Antiviral Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Influenza (Flu) Antiviral Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Influenza (Flu) Antiviral Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Influenza (Flu) Antiviral Drugs Sales Value by Application
  11. 5.3.1 Global Influenza (Flu) Antiviral Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Influenza (Flu) Antiviral Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Influenza (Flu) Antiviral Drugs Sales Value Share by Application (2021-2032)
6 Influenza (Flu) Antiviral Drugs Regional Sales and Value Analysis
  1. 6.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032)
  5. 6.3 Global Influenza (Flu) Antiviral Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Influenza (Flu) Antiviral Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Influenza (Flu) Antiviral Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Influenza (Flu) Antiviral Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Influenza (Flu) Antiviral Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Influenza (Flu) Antiviral Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Influenza (Flu) Antiviral Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Influenza (Flu) Antiviral Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Sales Value Share by Country, 2025 VS 2032
7 Influenza (Flu) Antiviral Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenza (Flu) Antiviral Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032)
  6. 7.4 Global Influenza (Flu) Antiviral Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Influenza (Flu) Antiviral Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Influenza (Flu) Antiviral Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Influenza (Flu) Antiviral Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Influenza (Flu) Antiviral Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Influenza (Flu) Antiviral Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Aurobindo Pharma
  8. 8.2.1 Aurobindo Pharma Company Information
  9. 8.2.2 Aurobindo Pharma Business Overview
  10. 8.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
  12. 8.2.5 Aurobindo Pharma Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Bristol-Myers-Squibb
  26. 8.5.1 Bristol-Myers-Squibb Company Information
  27. 8.5.2 Bristol-Myers-Squibb Business Overview
  28. 8.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  30. 8.5.5 Bristol-Myers-Squibb Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 F. Hoffmann-La Roche
  38. 8.7.1 F. Hoffmann-La Roche Company Information
  39. 8.7.2 F. Hoffmann-La Roche Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Recent Developments
  43. 8.8 Gilead Sciences
  44. 8.8.1 Gilead Sciences Company Information
  45. 8.8.2 Gilead Sciences Business Overview
  46. 8.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
  48. 8.8.5 Gilead Sciences Recent Developments
  49. 8.9 GlaxoSmithKline (GSK)
  50. 8.9.1 GlaxoSmithKline (GSK) Company Information
  51. 8.9.2 GlaxoSmithKline (GSK) Business Overview
  52. 8.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
  54. 8.9.5 GlaxoSmithKline (GSK) Recent Developments
  55. 8.10 Merck & Co. (MSD)
  56. 8.10.1 Merck & Co. (MSD) Company Information
  57. 8.10.2 Merck & Co. (MSD) Business Overview
  58. 8.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
  60. 8.10.5 Merck & Co. (MSD) Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Teva Pharmaceutical Industries
  68. 8.12.1 Teva Pharmaceutical Industries Company Information
  69. 8.12.2 Teva Pharmaceutical Industries Business Overview
  70. 8.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
  72. 8.12.5 Teva Pharmaceutical Industries Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 AbbVie
  80. 8.14.1 AbbVie Company Information
  81. 8.14.2 AbbVie Business Overview
  82. 8.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
  84. 8.14.5 AbbVie Recent Developments
  85. 8.15 Amgen
  86. 8.15.1 Amgen Company Information
  87. 8.15.2 Amgen Business Overview
  88. 8.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
  90. 8.15.5 Amgen Recent Developments
  91. 8.16 Bayer
  92. 8.16.1 Bayer Company Information
  93. 8.16.2 Bayer Business Overview
  94. 8.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
  96. 8.16.5 Bayer Recent Developments
  97. 8.17 Pfizer
  98. 8.17.1 Pfizer Company Information
  99. 8.17.2 Pfizer Business Overview
  100. 8.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
  102. 8.17.5 Pfizer Recent Developments
  103. 8.18 Eli Lilly
  104. 8.18.1 Eli Lilly Company Information
  105. 8.18.2 Eli Lilly Business Overview
  106. 8.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
  108. 8.18.5 Eli Lilly Recent Developments
  109. 8.19 Roche
  110. 8.19.1 Roche Company Information
  111. 8.19.2 Roche Business Overview
  112. 8.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  114. 8.19.5 Roche Recent Developments
  115. 8.20 Mylan
  116. 8.20.1 Mylan Company Information
  117. 8.20.2 Mylan Business Overview
  118. 8.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
  120. 8.20.5 Mylan Recent Developments
  121. 8.21 Novartis
  122. 8.21.1 Novartis Company Information
  123. 8.21.2 Novartis Business Overview
  124. 8.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
  126. 8.21.5 Novartis Recent Developments
  127. 8.22 Johnson & Johnson
  128. 8.22.1 Johnson & Johnson Company Information
  129. 8.22.2 Johnson & Johnson Business Overview
  130. 8.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
  132. 8.22.5 Johnson & Johnson Recent Developments
  133. 8.23 Sanofi
  134. 8.23.1 Sanofi Company Information
  135. 8.23.2 Sanofi Business Overview
  136. 8.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
  138. 8.23.5 Sanofi Recent Developments
  139. 8.24 Teva
  140. 8.24.1 Teva Company Information
  141. 8.24.2 Teva Business Overview
  142. 8.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
  144. 8.24.5 Teva Recent Developments
  145. 8.25 Takeda
  146. 8.25.1 Takeda Company Information
  147. 8.25.2 Takeda Business Overview
  148. 8.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
  150. 8.25.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
  2. 9.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza (Flu) Antiviral Drugs Sales Mode & Process
  6. 9.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza (Flu) Antiviral Drugs Distributors
  9. 9.2.3 Influenza (Flu) Antiviral Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst